Evidence map›Paper›PMID 34977205›Full record

ArticleFrontiers in veterinary science2021

Evaluation of Potency and Duration of Immunity Elicited by a Multivalent FMD Vaccine for Use in South Africa.

Faith R M Peta, M M Sirdar, Peter van Bavel, P B Mutowembwa, N Visser, J Olowoyo, M Seheri, Livio Heath

Open access · goldAbstract read
In one paragraph

Article in Frontiers in veterinary science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Frontiers in veterinary science · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Faith R M PetaTransboundary Animal Diseases: Vaccine Production Programme, Onderstepoort Veterinary Research Institute, Agricultural Research Council, Pretoria, South Africa.
M M SirdarTransboundary Animal Diseases: Vaccine Production Programme, Onderstepoort Veterinary Research Institute, Agricultural Research Council, Pretoria, South Africa.
Peter van BavelTransboundary Animal Diseases: Vaccine Production Programme, Onderstepoort Veterinary Research Institute, Agricultural Research Council, Pretoria, South Africa.
P B MutowembwaTransboundary Animal Diseases: Vaccine Production Programme, Onderstepoort Veterinary Research Institute, Agricultural Research Council, Pretoria, South Africa.
N VisserTransboundary Animal Diseases: Vaccine Production Programme, Onderstepoort Veterinary Research Institute, Agricultural Research Council, Pretoria, South Africa.
J OlowoyoDepartment of Biology, School of Science and Technology, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
M SeheriDepartment of Medical Virology, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
Livio HeathTransboundary Animal Diseases: Vaccine Production Programme, Onderstepoort Veterinary Research Institute, Agricultural Research Council, Pretoria, South Africa.
Onderstepoort Veterinary Institute · ZASefako Makgatho Health Sciences University · ZAPNO Consultants (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

South Africa (SA) experiences sporadic foot and mouth disease (FMD) outbreaks irrespective of routine prophylactic vaccinations of cattle using imported commercial vaccines. The problem could be mitigated by preparation of vaccines from local virus strains related to those circulating in the endemically infected buffalo populations in the Kruger National Park (KNP). This study demonstrates the individual number of protective doses (PD) of five vaccine candidate strains after homologous virus challenge, as well as the vaccines safety and onset of humoral immunity in naïve cattle. Furthermore, the duration of post-vaccination immunity over a 12-month period is shown, when a multivalent vaccine prepared from the five strains is administered as a primary dose with or without booster vaccinations. The five monovalent vaccines were shown to contain a 50% PD between 4 and 32, elicit humoral immunity with antibody titers ≥2.0 log10 from day 7 post-vaccination, and cause no adverse reactions. Meanwhile, the multivalent vaccine elicited antibody titers ≥2.0 log10 and clinical protection up to 12 months when one or two booster vaccinations were administered within 6 months of the primary vaccination. An insignificant difference between the application of one or two booster vaccinations was revealed. Owing to the number of PDs, we anticipate that the multivalent vaccine could be used successfully for prophylactic and emergency vaccinations without adjustment of the antigen payloads. Furthermore, a prophylactic vaccination regimen comprising primary vaccination of naïve cattle followed by two booster vaccinations 1.5 and 6 months later could potentially maintain herd immunity over a period of 12 months.

Indexed as

50% protective dose (potency)clinical protectionduration of immunityhumoral immunitySouth Africavaccine candidate

Identifiers

PMID34977205
PMCPMC8714748
OpenAlexW4200375727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.